Clinical Trials Directory

Trials / Conditions / Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8

Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8

10 registered clinical trials studyying Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v82 currently recruiting.

StatusTrialSponsorPhase
WithdrawnNeoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers
NCT05296005
Ohio State University Comprehensive Cancer CenterPhase 1
RecruitingPembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adeno
NCT05041153
M.D. Anderson Cancer CenterEARLY_Phase 1
Active Not RecruitingChemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of
NCT04929392
City of Hope Medical CenterPhase 2
Active Not RecruitingTesting the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advance
NCT04391049
NRG OncologyPhase 1
RecruitingRamucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Adv
NCT04660760
Academic and Community Cancer Research UnitedPhase 2
Active Not RecruitingTesting the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Eso
NCT04460937
National Cancer Institute (NCI)Phase 1
Active Not RecruitingPembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
NCT04522336
M.D. Anderson Cancer CenterPhase 1
CompletedUse of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esopha
NCT04097028
Roswell Park Cancer InstitutePhase 2
CompletedGenetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study
NCT03707574
National Cancer Institute (NCI)
Active Not RecruitingPhase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal
NCT03784326
M.D. Anderson Cancer CenterPhase 2